Phase 2 Study of the PARP Inhibitor Olaparib in IDH1/2-mutant solid tumors

Phase 2 Study of the PARP Inhibitor Olaparib in IDH1/2-mutant solid tumors

To conduct a comprehensive series of correlative studies in tumor biopsies to identify which patients with IDH1/2 tumor mutations respond best to the DNA repair inhibitor, Olaparib.

Lay Abstract

Our collaborative research group at Yale recently discovered that tumors with mutations in two key metabolism-related genes, IDH1 and IDH2, induce exquisite sensitivity to DNA repair inhibitors. In particular, the DNA repair inhibitor, olaparib, was recently FDA-approved for the treatment of ovarian cancers with gene mutations that induce a similar sensitivity. In this proposal, we will perform a clinical trial which will test whether olaparib is effective against tumors with IDH1 and IDH2 mutations. We will perform a comprehensive series of correlative studies in tumor biopsies, in order to identify which patients respond best. This study represents a true bench-to-bedside endeavor, and it leverages the best Yale science with the goal of improving the lives of cancer patients.